Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine.
Dr. Cohen previously served as Chair of the Board of the Biotechnology Innovation Organization (BIO), as Chair of the Emerging Companies Section of the BIO Board, and as Director and Chair of the New York Biotechnology Association (NYBA).He currently serves on the Board of Directors of VBL Therapeutics. Dr. Cohen was awarded Columbia University’s Alumni Medal for Distinguished Service.
Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year 2010 and was recognized by PharmaVoice Magazine in 2009 as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year and was named by MM&M/PR Week as one of the top 50 health influencers of 2017.
Burkhard Blank, M.D. has been Chief Medical Officer (CMO) at Acorda since July 2016. In January 2016, Dr. Blank was engaged by the Company to assume chief medical officer responsibilities on an interim basis.
Dr. Blank’s primary responsibilities include: setting strategy for and execution of development programs from clinical trials through regulatory filings; oversight of post-marketing studies for approved products; and management of the Company’s medical affairs, clinical operations, regulatory affairs, drug safety and biostatistics departments.
Dr. Blank has more than 25 years of industry experience, and previously served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim (BI). While at BI, he oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two U.S. Food and Drug Administration (FDA) Advisory Committee Meetings; subsequently, all five NDAs received FDA approval.
Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies.
Dr. Blank received his medical degree from Universitaet Marburg, Germany. He is board-certified in Germany in internal medicine.
Andrew R. Blight, Ph.D., has been Chief Scientific Officer at Acorda since January 2004. He served as Executive Vice President, Research and Development, from 2000 to 2004, and Vice President from 1998 to 2000. Before joining Acorda, Dr. Blight spent approximately six years as Professor and Director of the Neurosurgery Research Laboratory at the University of North Carolina at Chapel Hill. He held prior academic positions at Purdue University and New York University.
Dr. Blight is a leader in spinal cord injury (SCI) pathophysiology research and has made several important contributions to the field, particularly on the role of demyelination in SCI. He also pioneered the therapeutic application of 4-AP in SCI animal models and in human clinical trials.
Dr. Blight is a member of the editorial board of the Journal of Neurotrauma and has served as a member of the Neurological Sciences and Disorders-A (NSDA) review committee at the National Institutes of Health (NIH). He was previously Secretary, Treasurer and Vice President of the National Neurotrauma Society.
Dr. Blight received his B.S. in Zoology and his Ph.D. in Zoology/Neurobiology from the University of Bristol, U.K.
Denise Duca, Ed.M. has been Executive Vice President of Human Resources at Acorda since January 2015. She has held leadership positions of increasing responsibility in our HR department since 2002.
Ms. Duca received her B.A. in Professional Studies from Pace University, and an M.A. and Ed.M. in Psychological Counseling from Teachers College, Columbia University. She has also been a doctoral candidate in the Organization and Leadership Department at Teachers College, Columbia University.
Andrew A. Hindman joined Acorda in May 2014 as Chief Business Development Officer. Mr. Hindman is responsible for identifying and completing strategic transactions that expand the Company’s pipeline of commercial and development-stage products, as well as managing the Alliance Management function for existing partnerships. His role expanded in October 2016 to include financial planning and investor relations.
Mr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior to Tobira, Mr. Hindman held senior corporate development and commercial operating positions at Nodality, Onyx Pharmaceuticals and Gilead Sciences.
Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa, from Wesleyan University and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.
David Lawrence, M.B.A., David Lawrence, M.B.A., was appointed Chief, Business Operations in October 2013. In this role, Mr. Lawrence has oversight of Technical Operations/Manufacturing, Project Management, Information Technology and Facilities Management. In October 2016, he was named Principal Accounting Officer, assuming responsibility for the Company’s Accounting and Finance departments. From 2005 to 2013, he served as the Company’s Chief Financial Officer, and prior to 2005 he held various positions of increasing responsibility in the Finance department since joining Acorda in 1999. Between 1991 and 1999, Mr. Lawrence held several positions for Tel-Air Communications, Inc., including Vice President and Controller. Prior to Tel-Air, he held the financial management positions of Controller and Finance Manager for Southwestern Bell and Metromedia Telecommunications, respectively.
Mr. Lawrence received his B.A. in Accounting from Roger Williams College, and an M.B.A. in Finance from Iona College. Mr. Lawrence is a founding member, and currently serves on the Board of Directors as Treasurer, of The Brian Ahearn Children’s Fund.
Lauren Sabella has been Chief Commercial Officer at Acorda since February 2015. Ms. Sabella joined Acorda in 2010 as Executive Vice President of Commercial Development, with responsibility for the commercial launch of Ampyra (dalfampridine), including Marketing, Sales, Market Access, Trade Relations and Commercial Operations.
Before joining Acorda, Ms. Sabella was the Founder and Principal of Tugboat Consulting Group, an independent consulting practice assisting companies in the commercialization process. Ms. Sabella also served as Corporate Officer and Vice President of Commercial Development at Altus Pharmaceuticals, with responsibility for all aspects of commercialization. Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. In her last role, she served as Vice President of Sales, Eastern Zone, where she led the successful sales launch of Spiriva® (tiotropium bromide) and ran both Primary Care and Specialty Divisions, including Neurology, Urology and Cardio/Pulmonary. Prior to this role, she had over ten years of marketing experience where she led several product launches including Mobic® (meloxicam), an NSAID which became a $1 billion brand. Ms. Sabella holds a B.B.A. from Hofstra University.
Tierney Saccavino has been the Executive Vice President of Corporate Communications at Acorda Therapeutics since January 2015. She is responsible for the Company’s corporate communications, media relations, corporate website and social media programs, as well as its philanthropic giving, community outreach and consumer / advocacy relations. She has held various roles of increasing seniority in the Corporate Communications department since 1998.
Before joining Acorda Ms. Saccavino had over 15 years’ experience in public relations, marketing, and corporate communications. She was the Manager of Corporate Relations at Adventis, a Boston-based management consulting firm focusing on the media, communications, and telecom industries. In that capacity, she was responsible for public relations, corporate promotions, and executive education programs. She also worked for nine years in a variety of positions at Fidelity Investments. Ms. Saccavino attended the University of Connecticut in Storrs, Connecticut.
Jane Wasman, J.D. has been with Acorda since 2004. In 2012, she was named President, International. In this newly-created role, Ms. Wasman is leading the Company’s efforts to identify and launch in-licensing and commercial opportunities outside the United States.
Additionally, Ms. Wasman is responsible for the Company’s global strategic development, including the development and execution of Acorda’s long-range strategic plans and objectives, the analysis of trends, developments and contingencies that may impact the Company’s strategic courses of action, managing cross-functional integration among various departmental functions. She also continues to serve as Acorda’s General Counsel, managing the Company’s Legal/IP, Compliance and Quality departments, a position she has held since joining the company. She was named Chief, Strategic Development, in January 2012.
Before joining Acorda, Ms. Wasman was with Schering-Plough Corporation for eight years, holding various leadership positions, including Staff Vice President and Associate General Counsel. She was responsible for legal support for US Pharmaceuticals operations, including sales, marketing, and compliance; FDA regulatory matters; licensing and M&A; and, global research and development. She served as Staff Vice President, International in 2001, and as Staff Vice President, European Operations—Legal from 1998 to 2000.
Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate Counsel to the U.S. Senate Committee on Veterans’ Affairs. Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School. She is Chair of the Board of SELLAS Life Sciences and of their Nominating and Corporate Governance Committee as well as a member of the Board of Directors and of the Executive Committee of the Board of the New York Biotechnology Association.
You are now leaving the Acorda.com site. By clicking "Ok", you will be leaving this website (sponsored by Acorda Therapeutics, Inc.) to enter an external and entirely independent website.
Acorda.com provides this link as a service and assumes no responsibility for any information presented on external websites.
If you’ve been impacted by Hurricane Harvey, Irma, or Maria, and have concerns about your Ampyra (dalfampridine) prescription, please contact your Specialty Pharmacy or Ampyra Patient Support Services at (888) 881-1918
Acorda has acquired Biotie Therapies. We invite you to explore www.acorda.com to learn more about our company, including our continued development of BIotie clinical programs for tozadenant, SYN120 and BTT1023. Information regarding transfers of value made to healthcare professionals and healthcare organizations in connection with Biotie’s clinical development programs is also available.